Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study
Open accessAbstract
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study correspondence
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combining pembrolizumab with lenalidomide or pomalidomide and dexamethasone showed efficacy in single-arm trials but was associated with severe hematological and infectious toxicities and immune-related adverse events that led to termination of some clinical trials.
“Although single-agent activity was limited, combining pembrolizumab with lenalidomide or pomalidomide and dexamethasone showed efficacy in single-arm trials. However, these combinations were associated with severe hematological and infectious toxicities, as well as immune-related adverse events such as pneumonia, hypothyroidism, adrenal insufficiency, hepatitis, and vitiligo. These adverse events”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [181]
Cites
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, A., Hyjek, E., Ma, N., Lesokhin, A., Dogan, A., Rapoport, A. P., Kocoglu, M., Lederer, E., Philip, S., Milliron, T., et al. (2017) · Blood · doi:10.1182/blood-2017-03-775122 · Cited by 197 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works
- Authors
- Mateos, M., Orlowski, R. Z., Ocio, E. M., Rodríguez‐Otero, P., Reece, D., Moreau, P., Munshi, N., Avigan, D. E., Siegel, D. S., Ghori, R., Farooqui, M. Z. H., Marinello, P., & San-Miguel, J.
- Affiliations
- Complejo Asistencial Universitario de Salamanca/IBSAL & Centro de Investigación del Cáncer (IBMCC‐CSIC‐USAL) Salamanca Spain
- The University of Texas MD Anderson Cancer Center (US)
- Universidad de Cantabria (ES)
- Clinica Universidad de Navarra (ES)
- Princess Margaret Cancer Centre (CA)
- Centre Hospitalier Universitaire de Nantes (FR)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Hackensack University Medical Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Clinica Universidad de Navarra CIMA, IDISNA, CIBERONC Pamplona Spain
- ORCID
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2019-05-15
- Volume
- 186
- Issue
- 5
- Pages
- e117-e121
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2944998868
- Cited by
- 73
- References
- 1
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 9 · 2023: 7 · 2022: 11 · 2021: 17 · 2020: 17 · 2019: 6
- FWCI
- 9.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Haematology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Merck
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- pembrolizumab, lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, immune checkpoint inhibitors, combination therapy
- MeSH terms
- Lenalidomide, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
